- Home
- SKYE vs IAF Comparison
SKYE vs IAF Comparison
Compare SKYE & IAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- IAF
- Stock Information
- Founded
- SKYE 2012
- IAF 1985
- Country
- SKYE United States
- IAF United States
- Employees
- SKYE N/A
- IAF N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- IAF Finance/Investors Services
- Sector
- SKYE Health Care
- IAF Finance
- Exchange
- SKYE Nasdaq
- IAF Nasdaq
- Market Cap
- SKYE 121.8M
- IAF 127.6M
- IPO Year
- SKYE N/A
- IAF N/A
- Fundamental
- Price
- SKYE $1.33
- IAF $4.58
- Analyst Decision
- SKYE Strong Buy
- IAF
- Analyst Count
- SKYE 5
- IAF 0
- Target Price
- SKYE $14.75
- IAF N/A
- AVG Volume (30 Days)
- SKYE 1.8M
- IAF 90.4K
- Earning Date
- SKYE 11-06-2025
- IAF 01-01-0001
- Dividend Yield
- SKYE N/A
- IAF 11.44%
- EPS Growth
- SKYE N/A
- IAF N/A
- EPS
- SKYE N/A
- IAF N/A
- Revenue
- SKYE N/A
- IAF N/A
- Revenue This Year
- SKYE N/A
- IAF N/A
- Revenue Next Year
- SKYE N/A
- IAF N/A
- P/E Ratio
- SKYE N/A
- IAF N/A
- Revenue Growth
- SKYE N/A
- IAF N/A
- 52 Week Low
- SKYE $1.14
- IAF $3.60
- 52 Week High
- SKYE $5.96
- IAF $4.59
- Technical
- Relative Strength Index (RSI)
- SKYE 27.04
- IAF 52.15
- Support Level
- SKYE $1.50
- IAF $4.48
- Resistance Level
- SKYE $1.76
- IAF $4.65
- Average True Range (ATR)
- SKYE 0.24
- IAF 0.08
- MACD
- SKYE -0.15
- IAF -0.00
- Stochastic Oscillator
- SKYE 0.68
- IAF 65.63
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About IAF abrdn Australia Equity Fund Inc.
Aberdeen Australia Equity Fund Inc is a non-diversified closed-end investment management company. With a core focus on long-term capital appreciation, it invests predominantly in equity securities listed on the Australian Stock Exchange. Its secondary objective is current income, which it expects to derive from dividends and interest on Australian corporate and governmental securities. Its investment portfolio comprises diversified sectors that include Financials, Health Care, Materials, Information Technology, Real Estate, and other sectors.